Table of Contents

Webinar Registration Alert: Novel Platforms for Preclinical Antibody Discovery

Date: August 11, 2026

Time: 11:00 AM – 12:00 PM EDT

Featured Guest Speaker: Dr. Ivelin Georgiev

Monoclonal antibodies stand out as highly powerful preventive and therapeutic modalities against complex infectious diseases, diverse cancers, and autoimmune conditions. However, conventional antibody discovery workflows continue to hit a wall. Biopharma teams routinely confront significant systemic bottlenecks, including low biological screening efficiency, soaring experimental costs, high pipeline failure rates, logistical friction, and long turnaround times.

To overcome these roadblocks, our upcoming live event brings advanced computational design and wet-lab orchestration together. We are excited to invite Dr. Ivelin Georgiev to present his groundbreaking work on developing and validating integrated frameworks that transform the economics and speed of preclinical lead discovery.

1. Navigating Beyond the haystacks: Target-Specific AI Repertoires

Traditional discovery methodologies rely on isolating candidate molecules from a randomized biological library. Generative AI completely rewrites this timeline by shifting the paradigm from trial-and-error screening to target-informed sequence prediction. By utilizing deep learning models trained on vast structural datasets, algorithms can map target epitopes and predict exactly which amino acid structures will bind them with high affinity.

During the event, we will examine the data-driven mechanics of our advanced ai de novo antibody sequence generation service. This digital workflow explores massive sequence spaces entirely in silico, allowing developers to proactively filter for key manufacturability parameters—such as stability, low immunogenicity, and high expression potential—before initiating any physical synthesis.

2. Breaking Boundaries via Integrated Computational-Wet Lab Workflows

While generative modeling yields highly diverse virtual candidates, translating them into therapeutic realities requires high-throughput empirical validation. The core value of modern discovery lies in establishing a continuous loop where computational sequence design is immediately tested, refined, and verified by physical screening platforms.

Dr. Georgiev will detail how these integrated approaches function through our novel platforms for preclinical antibody discovery. Attendees will gain deep insight into how combining automation with machine learning algorithms enables teams to capture challenging antibody phenotypes that are difficult—or even impossible—to isolate using traditional hybridoma or early display technologies alone.

What the Session Will Cover:

How unified wet-lab and AI-based configurations optimize screening efficiency and success rates.

Strategies to integrate experimental workflows to minimize overall discovery costs, complexity, and pipeline turnaround times.

Real-world validation data uncovering rare antibody phenotypes designed for tricky, highly conserved targets.

Do not allow legacy library screening constraints to bottleneck your biological development pipeline. Reserve your complimentary virtual seat to participate in this high-impact industry discussion.